“Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s383. doi:10.25251/skin.8.supp.383.